(Total Views: 491)
Posted On: 08/07/2021 11:10:05 AM
Post# of 154912
Re: craigakess #99096
We've learned over the last 2 years that you either give up a percentage of revenue to a partner or you pay for it in dilution.
Who knows how much we could have gotten up front from a larger pharma instead of going with the crazy high royalty rate Vyera offered and getting almost all of the payments backloaded in milestones. And we probably would have had to dilute some anyway so Nader's approach may still work out better but nothing is free.
Shareholders were always going to give up a percentage one way or another because the first rule in business, and especially in clinical stage biotech, is that everything takes longer than expected.
Who knows how much we could have gotten up front from a larger pharma instead of going with the crazy high royalty rate Vyera offered and getting almost all of the payments backloaded in milestones. And we probably would have had to dilute some anyway so Nader's approach may still work out better but nothing is free.
Shareholders were always going to give up a percentage one way or another because the first rule in business, and especially in clinical stage biotech, is that everything takes longer than expected.
(4)
(0)
